PET radiotracer design for monitoring targeted immunotherapy

PET radiotracer design for monitoring targeted immunotherapy
Comparison of (A) Cu-64-DOTA-HACPD1, (B) Cu-64-NOTA-HAC-PD1, and (C) Cu-64-NOTA-HACA-PD1 ImmunoPET images acquired at 1h p.i. (~1.85 MBq/10 μg/200 μl) of NSG mice bearing dual subcutaneous tumors in shoulders (right = hPD-L1+; left = hPD-L1-). Panels left to right show representative coronal and axial cross sections of CT, PET, and merged PET/CT images with maximum intensity projection (MIP). White dashed line, coronal image, demarcation of axial cross-section; White dashed line, axial image, tumor boundary. SG, salivary gland; T+, hPD-L1 positive tumor; T-, hPD-L1 negative tumor; L, lung; Li, liver; K, kidney; B, bladder; H, heart. Scale bars represent 1 percent (blue) - 6 percent (red) ID/g. Tumor uptake was quantified using ROI analysis (right panel) without partial volume correction. Error bars represent SD. ns, not significant; *p<0.05, **p<0.01, ***p<0.001, student's T test. Credit: Sam Gambhir, MD, PhD, Stanford University

In an article published in the April issue of The Journal of Nuclear Medicine, researchers at Stanford University in California provide a template for assessing new positron emission tomography (PET) radiotracers that can accurately identify molecules in cancer cells that prevent the immune system from attacking the cancer.

A drug that blocks a cancer's inhibitory checkpoint molecules is called an and this form of immunotherapy has emerged as a promising cancer treatment approach. However, the lack of imaging tools to assess immune checkpoint expression has been a major barrier to predicting and monitoring response to a clinical checkpoint blockade.

"Because immunotherapies for cancer are expanding, methods to optimize them for an individual patient through are needed," explains Sam Gambhir, MD, PhD, at Stanford University. "Using animal models, this study shows the development of several new engineered PET tracers that can help image the immune system in action and be used to monitor checkpoint inhibitor therapy."

The study assessed practical immunoPET radiotracer design modifications and their effects onhuman PD-L1 immune checkpoint imaging. The researchers sought to optimize engineering design parameters including chelate, glycosylation, and radiometal to develop a non-invasive molecular imaging tool for eventual monitoring of clinical checkpoint blockade.

Gambhir points out, "This research will ultimately allow for translation to human imaging of the tracer that worked best in animal models. An effective immunoPET tracer will help patients receiving checkpoint inhibitor immunotherapy get optimal treatment and have the best chance for fighting their cancer."

Molecular imaging is playing an increasingly integral role in immunotherapy and personalized medicine. Looking ahead, Gambhir envisions "a lot more use of PET/CT or PET/MR imaging for patients undergoing immunotherapy." He adds, "This and related research will also help us develop other imaging approaches for understanding the immune system in action."

More information: "Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging", Journal of Nuclear Medicine (2017). DOI: 10.2967/jnumed.116.17765

Journal information: Journal of Nuclear Medicine
Citation: PET radiotracer design for monitoring targeted immunotherapy (2017, April 7) retrieved 25 April 2024 from https://medicalxpress.com/news/2017-04-pet-radiotracer-immunotherapy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Nanoparticle treatment could improve immunotherapy against cancer

8 shares

Feedback to editors